Maia Wealth LLC Makes New $211,000 Investment in Bristol-Myers Squibb (NYSE:BMY)

Maia Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,982 shares of the biopharmaceutical company’s stock, valued at approximately $211,000.

Other large investors also recently modified their holdings of the company. Csenge Advisory Group grew its holdings in Bristol-Myers Squibb by 12.0% during the 1st quarter. Csenge Advisory Group now owns 9,484 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 1,018 shares in the last quarter. Advisory Alpha LLC grew its stake in Bristol-Myers Squibb by 73.2% during the first quarter. Advisory Alpha LLC now owns 10,048 shares of the biopharmaceutical company’s stock valued at $545,000 after acquiring an additional 4,245 shares in the last quarter. Advisory Services Network LLC increased its holdings in Bristol-Myers Squibb by 47.0% in the 1st quarter. Advisory Services Network LLC now owns 119,423 shares of the biopharmaceutical company’s stock valued at $6,476,000 after acquiring an additional 38,163 shares during the last quarter. CFO4Life Group LLC bought a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at about $233,000. Finally, Empirical Finance LLC grew its position in shares of Bristol-Myers Squibb by 3.2% during the first quarter. Empirical Finance LLC now owns 77,242 shares of the biopharmaceutical company’s stock valued at $4,189,000 after purchasing an additional 2,429 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Transactions at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Samit Hirawat purchased 1,830 shares of the stock in a transaction dated Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the transaction, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on BMY shares. TD Cowen increased their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. UBS Group boosted their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 9th. Barclays boosted their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. BMO Capital Markets increased their price target on shares of Bristol-Myers Squibb from $53.00 to $57.00 and gave the company a “market perform” rating in a report on Friday, November 1st. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $53.00.

Bristol-Myers Squibb Stock Performance

BMY stock opened at $55.28 on Thursday. The business’s fifty day simple moving average is $51.69 and its two-hundred day simple moving average is $46.72. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The firm has a market cap of $112.12 billion, a price-to-earnings ratio of -15.40, a PEG ratio of 13.14 and a beta of 0.44. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $56.80.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period last year, the company posted $2.00 earnings per share. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. Analysts predict that Bristol-Myers Squibb will post 0.83 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.34%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is -66.85%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.